Anti-depressive Therapies After Heart Transplantation

Journal of Heart and Lung Transplantation

Volumn 25, Issue 7, 2006, Pages 785-793

  Fusar Poli, Paolo ^a   Picchioni, Marco ^b   Martinelli, Valentina ^a   Bhattacharyya, Sagnik ^b   Cortesi, Mariachiara ^a   Barale, Francesco ^a   Politi, Pierluigi ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CARBAMAZEPINE; CITALOPRAM; CORTICOSTEROID; CYCLOSPORIN; DESIPRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUOXETINE; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; HYPERTENSIVE AGENT; IMMUNOSUPPRESSIVE AGENT; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VASODILATOR AGENT;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; BRAIN HEMORRHAGE; CARDIAC GRAFT REJECTION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INTOXICATION; DRUG OVERDOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG USE; ELECTROCONVULSIVE THERAPY; EMBASE; HEART GRAFT; HEART HEMODYNAMICS; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSOMNIA; KIDNEY DYSFUNCTION; LIFE; LIVER TOXICITY; MAJOR DEPRESSION; MANIA; MEDLINE; METHODOLOGY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PATIENT CARE; POPULATION; PRIORITY JOURNAL; PSYCHOTHERAPY; PSYCINFO; QUALITATIVE ANALYSIS; RECIPIENT; REVIEW; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SHOCK; SIDE EFFECT; SINUS NODE DYSFUNCTION; T WAVE INVERSION; TACHYCARDIA; THREAT; TREMOR; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; DEPRESSION; ELECTROCONVULSIVE THERAPY; HEART TRANSPLANTATION; HUMANS; TREATMENT OUTCOME;

EID: 33745487370     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2006.03.019     Document Type: Review

References (110)

1. Taylor D., Leah B., and Mark M. The registry of the International Society of Heart and Lung Transplantation. twenty-first official adult heart transplant report-2004. J Heart Lung Transplant 23 (2004) 796-803
2. Grady K. Quality of life after heart transplantation. are things really better?. Curr Opin Cardiol 18 (2003) 129-135
3. Robbins R., Barlow C., and Oyer P. Thirty years of cardiac transplantation at Stanford University. J Thorac Cardiovasc Surg 14 (1999) 373-381
4. Karam V., Gasquet I., and Delvart V. Quality of life in adult survivors beyond 10 years after liver, kidney and heart transplantation. Transplantation 64 (2003) 1261-1273
5. Grady K., Meyer P., and Dressler D. Change in quality of life after ventricular assist device implantation after heart transplantation. J Heart Lung Transplant 22 (2003) 1254-1267
6. Grady K.L., Naftel D.C., White-Williams C., et al. Predictors of quality of life at 5 to 6 years after heart transplantation. J Heart Lung Transplant 24 (2005) 1431-1439
7. Barr M., Schenkel F., and Van Kirk A. Determinants of quality of life changes among long-term cardiac transplant survivors. results from longitudinal data. J Heart Lung Transplant 22 (2003) 1157-1167
8. Politi P., Piccinelli M., and Fusar-Poli P. Ten years of "extended life". quality of life among heart transplant survivors. Transplantation 78 (2004) 257-263
9. Dew M., Roth L., and Schulberg H. Prevalence and predictors of depression and anxiety-related disorders during the year after transplantation. Gen Hosp Psychiatry 18 (1996) 48-61
10. Dew M. Psychiatric disorders in the context of physical illness. In: Dohrenwend B.P. (Ed). Adversity, stress and psychopathology (1998), Oxford University Press, New York 177-218
11. Zipfel S., Lowe B., and Paschke T. Psychological distress in patients awaiting heart transplantation. J Psychosom Res 45 (1998) 465-470
12. Engle D. Psychosocial aspects of the organ transplant experience. what has been established and what we need for the future. J Clin Psychol 57 (2001) 521-549
13. Wray J., and Radley-Smith R. Depression in pediatric patients before and 1 year after heart or heart-lung transplantation. J Heart Lung Transplant 23 (2004) 1103-1110
14. Evangelista L., Moser D., and Dracup K. Functional status and perceived control influence quality of life in female heart transplant recipients. J Heart Lung Transplant 23 (2004) 360-367
15. Bunzel B., and Laederach-Hofmann K. Long-term effects of heart transplantation. the gap between physical performance and emotional well-being. Scand J Rehabil Med 31 (1993) 222
16. Evangelista L., Doering L., Dracup K., et al. Hope, mood states and quality of life in female heart transplant recipients. J Heart Lung Transplant 22 (2003) 681-686
17. Fusar-Poli P., Martinelli V., Klersy C., et al. Depression and quality of life in patients living 10 to 18 years after heart transplantation. J Heart Lung Transplant 24 (2005) 2269-2278
18. Jonas B., and Mussolino M. Symptoms of depression as a prospective risk factor for stroke. Psychosom Med 62 (2000) 463-471
19. Triffaux J., Wauthy J., and Bertrand J. Psychological evolution and assessment in patients undergoing orthotopic heart transplantation. Eur Psychiatry 16 (2001) 180-185
20. Murray J. Cardiac disorders and antidepressant medications. J Psychol 134 (2000) 162-168
21. Pacher P., and Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics. new drugs, old concerns?. Curr Pharm Des 10 (1999) 2463-2475
22. Roose S., and Glassmann A. Antidepressant choice in the patient with cardiac disease. lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. J Clin Psychiatry 55 (1994) 98-100
23. Roose S., Devanand D., and Suthers K. Depression. treating the patient with comorbid cardiac disease. Geriatrics 54 (1999) 29-31
24. Pacher P., Ungvari Z., and Nanasi P. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any?. Curr Med Chem 6 (1999) 469-480
25. Trzepacz P., Levenson J., and Tringali R. Psychopharmacology and neuropsychiatric syndromes in organ transplantation. Gen Hosp Psychiatry 13 (1991) 233-245
26. Shapiro P. Nortriptyline treatment of depressed cardiac transplant recipients. Am J Psychiatry 148 (1991) 371-373
27. Kay J., Bienefeld D., and Slomowitz M. Use of tricyclic antidepressants in recipients of heart transplants. Psychosomatics 32 (1991) 165-169
28. Morganroth J., and Goin J. Quinidine-related mortality in the short to medium term treatment of ventricular arrhythmias. Circulation 84 (1991) 1977-1991
29. Glassmann A., Roose S., and Bigger J. The safety of tricyclic antidepressants in cardiac patients. risk-benefit reconsidered. JAMA 269 (1993) 2673-2675
30. Glassmann A., and Preud'homme X. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 54 (1993) 16-22
31. Burggraf G. Are psychotropic drugs at therapeutic levels a concern for cardiologists?. Can J Cardiol 13 (1997) 75-80
32. Ogawa Y., Tenderich G., and Minami K. Successful use of a cardiac allograft from tricyclic antidepressant intoxication. Transplantation 76 (2003) 1239-1241
33. Perry P., Zelimann C., and Arndt S. Tricyclic antidepressant concentrations in plasma. an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 14 (1994) 230-240
34. Serkova N., Christians U., and Benet L. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Intervent 4 (2004) 97-107
35. Fobe F., Kesterns-Servaye Y., and Baele P. Heart-transplant and mono-amine oxidase inhibitors. Acta Anaesthesiol Belg 40 (1989) 131-138
36. Levenson J., and Olbrisch M. Psychiatric aspects of heart transplantation. Psychosomatics 34 (1993) 114-123
37. Anderson I. Meta analytical studies on new antidepressants. Br Med Bull 57 (2001) 161-178
38. Roose S. Depression, anxiety and the cardiovascular system. the psychiatric's perspective. J Clin Psychiatry 62 (2001) 19-22
39. Yeragani V., Pesce V., and Jayataman A. Major depression with ischemic heart disease. effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol Psychiatry 2002 (2002) 418-429
40. Rasmussen S., Overo K., and Tanghoj P. Cardiac safety of citalopram. prospective trials and retrospective analysis. J Clin Psychopharmacol 19 (1999) 407-415
41. Ibister G., Bowe S., and Dawson. A Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. Int Clin Psychopharmacol 11 (1996) 35-40
42. Wu C., Benet L., and Hebert M. Differentiation of absorption and first-pass gut and hepatic metabolism in humans. studies with cyclosporine. Clin Pharmacol Ther 58 (1995) 497
43. Havrey A., and Preskorn S. Cytochrome P450 enzymes. interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 16 (1996) 345-355
44. Campana C., Regazzi M., and Buggia I. Clinically significant drug interactions with cyclosporine. An update. Clin Pharmacokinet 30 (1996) 141-179
45. Horton R., and Bonser R. Interaction between cyclosporin and fluoxetine. BMJ 311 (1995) 422
46. Vella J., and Sayegh M. Interactions between cyclosporine and newer antidepressant medications. Am Kidney Dis 31 (1998) 320-323
47. Roose S., Glassmann A., and Attia E. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 155 (1998) 600-665
48. Markowitz J., Gill H., and Hunt N. Lack of antidepressant-cyclosporine pharmacokinetic interactions. J Clin Psychopharmacol 18 (1998) 91-93
49. Strouse T., Fairbanks L., and Skotzko C. Fluoxetine and cyclosporine in organ transplantation. Failure to detect significant drug interactions or adverse clinical events in depressed organ recipients. Psychosomatics 37 (1996) 23-30
50. Liston H., Markowitz J., and Hunt N. Lack of citalopram effect on the pharmacokinetics of ciclosporine. Psychosomatics 42 (2001) 270-274
51. Willets J., Lippa A., and Beer B. Clinical development of citalopram. J Clin Psychopharmacol 19 (1999) 36-46
52. Wright D., Lake K., and Bruhn P. Nefazodone and cyclosporine drug-drug interaction. J Heart Lung Transplant 18 (1999) 913-915
53. Helms-Smith K., Curtis S., and Hatton R. Apparent interaction between nefazodone and cyclosporine. Ann Intern Med 125 (1996) 424
54. Campo J., Smith C., and Perel J. Tacrolimus toxic reaction associated with use of nefazodone. paroxetine as an alternative agent. Arch Gen Psychiatry 55 (1998) 1051
55. Glassmann A., O'Connor C., Califf R., and Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288 (2002) 701-709
56. Miller M. Depression after cardiac transplant treated with interpersonal psychotherapy and paroxetine. Am J Psychother 56 (2002) 555-561
57. Van Melle J., Buikema H., and Van Den Berg M. Sertraline causes strong coronary vasodilation. possible relevance for cardioprotection by selective serotonin reuptake inhibitors. Cardiovasc Drugs Ther 18 (2004) 441-447
58. Schlienger R., and Meier C. Effect of selective serotonin reuptake inhibitors on platelet activation. can they prevent acute myocardial infarction?. Am J Cardiovasc Drugs 3 (2003) 149-162
59. Hayes D. Recent developments in antidepressant therapy in special populations. Am J Manag Care 10 (2004) 179-185
60. Keltner N., McAfee K., and Taylor C. Mechanisms and treatments of SSRI-induced sexual dysfunction. Perspect Psychiatric Care 38 (2002) 111-116
61. Nutt D. Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol 17 (2002) 37-41
62. Crone C., and Gabriel G. Treatment of anxiety and depression in transplant patients. pharmacokinetic considerations. Clin Pharm 43 (2004) 361-394
63. Shapiro P. Psychiatric aspects of cardiovascular disease. Psychiatric Clin N Am 19 (1996) 613-629
64. Risch S., Groom G., and Janoesky D. The effects of psychotropic drugs on the cardiovascular system. J Clin Psychiatry 43 (1982) 16-31
65. Tilkian A., Schroeder J., and Kao J. The cardiovascular effects of lithium in man. A review of the literature. Am J Med 61 (1976) 665-670
66. Vincent H., Wenting G., and Schalekamp M. Impaired fractional excretion on lithium. a very early marker of cyclosporine toxicity. Transplant Proc 19 (1987) 4147-4148
67. Cooney G., Mochon M., and Kaiser B. Effect of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. Pharmacotherapy 15 (1995) 353-356
68. Alvarez S., Del Castillo S., and Ortiz A. Effect of carbamazepine on cyclosporin blood level. Nephron 58 (1991) 235-236
69. DasGutta K., and Jefferson J. The use of lithium in the medically ill. Gen Hosp Psychiatry 12 (1990) 83-97
70. Ernst E., Pittler M., and Stevenson C. Risks associated with complementary therapies. In: Schaffner A. (Ed). Meyler's side effects of drugs (2000), Excerpta Medica, Amsterdam 1649-1681
71. Linde K., Ramirez G., and Mulrow C. St John's wort for depression. an overview and meta-analysis of randomised clinical trials. BMJ 313 (1996) 258
72. Wong A., Smith M., and Boon H. Herbal remedies in psychiatry practice. Arch Gen Psychiatry 55 (1998) 1033-1044
73. Ernst E. St John's wort supplements endanger the success of organ transplantation. Arch Gen Surg 137 (2002) 316-319
74. Knuppel L., and Linde K. Adverse effects of St John's wort. a systematic review. J Clin Psychiatry 65 (2004) 1470-1479
75. Czekalla J., Gastpar M., and Hubner W. The effect of hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopsychiatry 30 (1997) 86-88
76. Hammemess P., Basch E., and Ulbrischt C. St. John wort. a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 44 (2003) 271-282
77. Ernst E. Interactions between synthetic and herbal medicinal products. part 2, a systematic review of the indirect evidence. Perfusion 13 (2000) 60-70
78. Ernst E. Interactions between synthetic and herbal medicinal products. part 1, a systematic review of the indirect evidence. Perfusion 13 (2000) 8-15
79. Bon S. Johanniskraut ein enzyminduktor. Schweitzer Apothekerzeitung 16 (1999) 535-536
80. Ruschitzka F., Meier P., Turina M., et al. Acute heart transplant rejection due to St John's wort. Lancet 355 (2000) 548-549
81. Moore L., Goodwin J., and Jones S. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci 97 (2000) 7502
82. Roby C. Inhibition of human cytochrome P450 enzymes by constituents of St John's wort. effect on CYP3A4 activity. Clin Pharmacol Ther 67 (2000) 451-457
83. Budzinski J.W. An in vitro evaluetion of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 7 (2000) 282
84. Lill J., Bauer L., and Horn J. Cyclosporine-drug interaction and the influence of patient age. Am J Health Syst Pharm 57 (2000) 1579-1584
85. Rabheru K. The use of electroconvulsive therapy in special patient populations. Can J Psychiatry 46 (2001) 710-719
86. Zielinski R., Roose S., and Devanand D. Cardiovascular complications of ECT in depressed patients with cardiac disease. Med J Psychiatry 150 (1993) 904-909
87. Rice E., Sombrotto L., and Markowitz J. Cardiovascular morbidity in high-risk patients during ECT. Am J Psychiatry 151 (1994) 1673-1681
88. Kellner C., Monroe R., and Burns C. Electroconvulsive therapy in a patient with a heart transplant. N Engl J Med 325 (1991) 663
89. Jones R., and Knight P. Cardiovascular and hormonal responses to electroconvulsive therapy. Anaesthesia 36 (1981) 799
90. Jones E. Cardiac transplantation and depression. Am J Psychiatry 148 (1991) 1271
91. Pargger H., Kaufmann M., and Schouten R. Hemodynamic responses to electroconvulsive therapy in a patient 5 years after cardiac transplantation. Anesthesiology 83 (1995) 625-627
92. Mortara A. The neurovegetative system in heart failure and heart transplantation. Ital Heart J 2 suppl (2001) 871-877
93. Bengel F., Ueberfuhr P., Karja J., Schreiber K., and Nekolla S. Sympathetic reinnervation, exercise performance and effects of β-adrenergic blockade in cardiac transplant recipients. Eur Heart J 25 (2004) 1726-1733
94. Applegate R. Diagnosis and management of ischemic heart disease in the patient scheduled to undergo electroconvulsive therapy. Convulsive Ther 7 (1997) 93
95. Linden W. Psychological treatments in cardiac rehabilitation. review of rationales and outcomes. J Psychosom Res 48 (2000) 443-454
96. Martensson J., Dracup K., Canary C., and Fridlund B. Living with heart failure. depression and quality of life in patients and spouses. J Heart Lung Transplant 22 (2003) 460-467
97. Allan R., and Scheidt S. Group psychotherapy for patients with coronary heart disease. Int J Group Psychother 48 (1998) 187-214
98. Rosenfeld D., and Cvik N. Psychosis and cardiac transplant. The psychotic aspects of the personality (1992), Karnac Books, London
99. Mayou R., Gill D., and Thompson D. Depression and anxiety as predictors of outcome after myocardial infarction. Psychosom Med 62 (2000) 212-219
100. Barefoot J., and Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 93 (1996) 1976-1980
101. Freedland K., Lustman P., and Carney R. Underdiagnosis of depression in patients with coronary artery disease. the role of non-specific symptoms. Int J Psychiatry Med 22 (1992) 221-229
102. Ziegestein R. Depression in patients recovering from a myocardial infarction. JAMA 286 (2001) 1621-1627
103. Fava M., Abraham M., and Pava J. Cardiovascular risk factors in depression. the role of anxiety and anger. Psychosomatics 37 (1996) 53-71
104. De Vito Dabbs A., Dew M.A., et al. Psychosocial vulnerability, physical symptoms and physical impairment after lung and heart-lung transplantation. J Heart Lung Transplant 22 (2003) 1268-1275
105. Hirschfeld R., Keller M., and Panico S. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 277 (1997) 333-340
106. Tenderich G., Dagge A., and Schulz U. Successful use of cardiac allograft from serotonin antagonist intoxication. Transplantation 77 (2001) 529-530
107. Hesslinger B., Van De Loo A., and Klecha D. Depression and panic disorder after heart transplantation-treatment with sertraline. Pharmacopsychiatry 35 (2002) 32
108. Wobrock T., Schwaab B., and Bohm M. Pharmacotherapeutical approaches in insomniac patients with cardiac diseases and after transplantation. Zeitscrift fur Kardiologie 90 (2001) 717-728
109. Lee H., Jayaram G., and Teitelbaum M. Electroconvulsive therapy for depression in a cardiac transplant patient. Psychosomatics 42 (2001) 362-364
110. Bloch M., Admon D., and Bonne O. Electroconvulsive therapy in a depressed heart transplant patient. Convulsive Ther 8 (1992) 290-293